title: Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.
abstract: A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1,500 kcal day(-1) were included. Chemotherapy, with cisplatin 30 mg m(-2) and irinotecan 60 mg m(-2), was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44-79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4-72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3-77.3%) and 27.9% (95% CI, 13.4-41.3%), respectively. In conclusion, cisplatin-irinotecan-radiotherapy is an active and well-tolerated regimen feasible in out-patients.
authors.affiliation: Unité d'oncologie digestive, Service d'Hepato-Gastroenterologie, CHU de Rouen, 1 rue de Germont 76031 Rouen Cedex, France. pierre.michel@chu-rouen.fr
authors.forename: P
authors.initials: P
authors.lastname: Michel
authors.forename: A
authors.initials: A
authors.lastname: Adenis
authors.forename: F
authors.initials: F
authors.lastname: Di Fiore
authors.forename: E
authors.initials: E
authors.lastname: Boucher
authors.forename: M P
authors.initials: MP
authors.lastname: Galais
authors.forename: L
authors.initials: L
authors.lastname: Dahan
authors.forename: X
authors.initials: X
authors.lastname: Mirabel
authors.forename: H
authors.initials: H
authors.lastname: Hamidou
authors.forename: J L
authors.initials: JL
authors.lastname: Raoul
authors.forename: J H
authors.initials: JH
authors.lastname: Jacob
authors.forename: M F
authors.initials: MF
authors.lastname: Hellot
authors.forename: S
authors.initials: S
authors.lastname: Prod'homme
authors.forename: B
authors.initials: B
authors.lastname: Paillot
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy / Q000009:adverse effects; D003680:Deglutition Disorders / Q000209:etiology; D019583:Dose Fractionation, Radiation; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin